Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
anti-LRP5/6, mAb (rec.) (Heldy-1-4)
480
CHF
CHF 480.00
In stock
AG-27B-0019-C100100 µgCHF 480.00
Figure 1: Detection of endogenous mouse LRP5/6 using anti-LRP5/6, mAb (rec.) (Heldy-1-4) (Prod. No. AG-27B-0019). Method: B16 melanoma mouse cells were stained with anti-LRP5/6, mAb (rec.) (Heldy-1-4) (blue and red lines) (1/100 in PBS + 2% FCS) or with the secondary antibody alone as control (gray area) for 1h at 4°C. The staining was revealed with a secondary anti-human IgG-PE (1/200) and then analyzed by flow cytometry. The blue and red lines represent two different lots of anti-LRP5/6, mAb (rec.) (Heldy-1-4). Picture courtesy of Prof. Werner Held lab, Ludwig Institute for Cancer Research, Lausanne, Switzerland.
Figure 2: Detection of overexpressed human LRP6 using anti-LRP5/6, mAb (rec.) (Heldy-1-4) (Prod. No. AG-27B-0019). Method: HEK293 cells transfected (green line) or mock transfected (black line) with a dicistronic plasmid encoding for human LRP6 and GFP, were stained with anti-LRP5/6, mAb (rec.) (Heldy-1-4) (1/100 in PBS + 2% FCS) or with the secondary antibody alone as control (gray area) for 1h at 4°C. The staining was revealed with an anti-human IgG PE (1/200) and then analyzed by flow cytometry. Picture courtesy of Prof. Werner Held lab, Ludwig Institute for Cancer Research, Lausanne, Switzerland.
Figure 3: Structure of the recombinant antibody anti-LRP5/6, mAb (rec.) (Heldy-1-4) (Prod. No. AG-27B-0019). The single chain variable human fragment (ScFv) selected by antibody phage display technology and specific to the antigen of interest is fused to a human IgG2 Fc region.
| Product Details | |
|---|---|
| Synonyms | Low-density Lipoprotein Receptor-related Protein 5; LRP-5; Low-density Lipoprotein Receptor-related Protein 6; LRP-6 |
| Product Type | Recombinant Antibody |
| Properties | |
| Clone | Heldy-1-4 |
| Isotype | Human IgG2λ. |
| Source/Host | Produced without the use of animals. Purified from HEK 293 cell culture supernatant. |
| Immunogen/Antigen | Recombinant mouse LRP6. |
| Application |
Flow Cytometry: 1/100 dilution |
| Crossreactivity |
Human Mouse |
| Specificity |
Recognizes human and mouse LRP5 & LRP6. |
| Purity | ≥95% (SDS-PAGE) |
| Purity Detail | Protein A-affinity purified. |
| Concentration | 1mg/ml |
| Formulation | Liquid. In PBS containing 10% glycerol. |
| Isotype Negative Control | |
| Other Product Data |
anti-LRP5/6 (human), mAb (rec.) (Heldy-1-4) is composed of human variable regions (VH and VL) (λ-chain) of immunoglobulin fused to the human lgG2 Fc domain. |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. |
| Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Wnt/β-catenin signaling acts as a regulator of tissue development and homeostasis. Wnt ligands bind to a member of the Frizzled family of seven-transmembrane proteins and to either highly homologous low-density lipoprotein related receptors 5 (LRP5) or LRP6. Low-density lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor (LDLR) family. LRP5 and LRP6 are expressed in most human tissues and is composed of three distinctive cell-surface protein domains, including (1) LDL receptor (LDLR) type A repeats; (2) an epidermal growth factor (EGF)-like domain; and (3) a YWTD (Tyr-Trp-Thr-Asp)-type β propeller domain. LRP6 is inhibited by the Dickkopf protein Dkk1 bound to their partners Kremen. Sclerotin also acts as an inhibitor of LRP5/6 through LRP4. LRP6 is involved in cell differentiation, proliferation and migration during embryonic development and in the pathogenesis of different cancer types. LRP6 plays a major role in metabolic regulation, specifically in the nutrient-sensing pathway. Patients carrying an LRP6 mutation exhibit high serum LDL cholesterol and triglycerides, hypertension, high fasting blood glucose levels, a prevalence of diabetes and low bone density. LRP6 mutations have also been associated with diseases such as Alzheimer's and degenerative joint diseases. LRP5, low-density-lipoprotein-receptor-related protein 5, is a determinant for bone mineral density and plays a role in osteoporosis. LRP5 is aso involved in vitreoretinopathy.
Related Products
